CompletedNot Applicable

Follow up After Cryoablation of Small Renal Masses.

Netherlands9 participantsStarted 2015-02

Plain-language summary

Currently there is no consensus on post procedural follow up imaging following percutaneous cryoablation of renal tumors. Interpretation of conventional contrast enhanced imaging (CT and MRI) during follow up can be very challenging. The objective of this study is to evaluate the feasibility of early evaluation of the therapeutic effect by performing early follow up imaging after percutaneous MR-guided cryoablation of pT1a renal cell carcinoma using 111In-Girentuximab-DOTA SPECT CT imaging.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * \>50 years of age; * At least one untreated T1a tumour of one kidney (tumour ≤ 4 cm in greatest dimension); * Signed IRB-approved informed consent form. Exclusion Criteria: * Pregnancy or breast feeding; * Known hypersensitivity or HACA against Girentuximab. * Administration of experimental medication for imaging purposes within three months before administration of Indium-111-Girentuximab for this study, except the administration of Girentuximab labeled with a random isotope.

What they're measuring

Predictive value.

Timeframe: Up to at least 3 months following initial treatment (cryoablation).

Trial details

NCT IDNCT02411968

SponsorRadboud University Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-09

View on ClinicalTrials.gov More Carcinoma, Renal Cell trials